We are live on ! Find out more
PA

Perceptive Advisors Portfolio holdings

AUM $6.66B
1-Year Est. Return 360.84%
This Fund
S&P 500
This Quarter Est. Return
+35.24%
1 Year Est. Return
+360.84%
3 Year Est. Return
+1,707.27%
5 Year Est. Return
+3,210.42%
10 Year Est. Return
+53,055.89%
AUM
$3.54B
AUM Growth
+$917M
Cap. Flow
+$107M
Cap. Flow %
3.03%
Top 10 Hldgs %
51.42%
Holding
131
New
31
Increased
26
Reduced
8
Closed
26

Top Buys

Rank Stock Value
1
ARRY
Array Biopharma Inc
ARRY
+$88M
2
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$70.6M
3
BPMC
Blueprint Medicines
BPMC
+$30.6M
4
AMRN
Amarin Corp
AMRN
+$30M
5
TDOC icon
Teladoc Health
TDOC
+$26.6M

Top Sells

Rank Stock Value
1
SLDB icon
Solid Biosciences
SLDB
+$105M
2
NBIX icon
Neurocrine Biosciences
NBIX
+$71M
3
ARGX icon
argenx
ARGX
+$53.9M
4
LJPC
La Jolla Pharmaceutical Company
LJPC
+$41M
5
XLRN
Acceleron Pharma
XLRN
+$39.9M

Sector Composition

Rank Sector Weight
1 Healthcare 96.08%
2 Miscellaneous 2.54%
3 Consumer Staples 0.8%
4 Financials 0.51%
5 Technology 0.04%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
AORT icon
76
Artivion
AORT
$1.24B
$1.46M 0.04%
+50,000
New +$1.43M
ABEO icon
77
Abeona Therapeutics
ABEO
$313M
$1.33M 0.04%
7,232
– –
AVDR
78
DELISTED
Avedro, Inc Common Stock
AVDR
$1.23M 0.03%
+100,000
New +$1.25M
ALNA
79
DELISTED
Allena Pharmaceuticals
ALNA
$929K 0.03%
132,300
– –
RACE icon
80
Ferrari
RACE
$71.5B
$830K 0.02%
6,200
– –
TNDM icon
81
Tandem Diabetes Care
TNDM
$1.13B
$816K 0.02%
12,844
– –
VCYT icon
82
Veracyte
VCYT
$3.23B
$789K 0.02%
+31,521
New +$602K
AXSM icon
83
Axsome Therapeutics
AXSM
$10.7B
$767K 0.02%
+53,879
New +$500K
CLVS
84
PUT
DELISTED
Clovis Oncology, Inc.
CLVS
$660K 0.02%
+200,000
New +$5.01M
BIIB icon
85
CALL
Biogen
BIIB
$31.9B
$620K 0.02%
+400,000
New +$126M
LAB icon
86
Standard BioTools
LAB
$271M
$612K 0.02%
+46,030
New +$485K
KYNB
87
Kyntra Bio
KYNB
$31.5M
$506K 0.01%
+372
New +$505K
VCEL icon
88
Vericel Corp
VCEL
$2.03B
$492K 0.01%
28,090
– –
SRPT icon
89
CALL
Sarepta Therapeutics
SRPT
$2.19B
$421K 0.01%
+100,000
New +$12.9M
ACAD icon
90
Acadia Pharmaceuticals
ACAD
$4.61B
$400K 0.01%
+14,897
New +$348K
BEAT
91
DELISTED
BioTelemetry, Inc.
BEAT
$399K 0.01%
+6,369
New +$437K
EOLS icon
92
Evolus
EOLS
$522M
$344K 0.01%
+15,232
New +$329K
OTLKW
93
DELISTED
Outlook Therapeutics, Inc. Series A Warrant Expiring 02/18/2022
OTLKW
$159K ﹤0.01%
420,875
– –
AGIO icon
94
CALL
Agios Pharmaceuticals
AGIO
$1.96B
$140K ﹤0.01%
+200,000
New +$11.6M
CLVS
95
CALL
DELISTED
Clovis Oncology, Inc.
CLVS
$125K ﹤0.01%
+200,000
New +$5.01M
IMMU
96
CALL
DELISTED
Immunomedics Inc
IMMU
$125K ﹤0.01%
200,000
– –
ASND icon
97
PUT
Ascendis Pharma A/S
ASND
$15.8B
$25K ﹤0.01%
+200,000
New +$17.5M
ONCS
98
DELISTED
OncoSec Medical Incorporated
ONCS
$17K ﹤0.01%
136
-91
-40% -$12.4K
IMGN
99
CALL
DELISTED
Immunogen Inc
IMGN
$15K ﹤0.01%
+600,000
New +$2.6M
ADVM
100
DELISTED
Adverum Biotechnologies
ADVM
– –
-30,000
Closed -$960K
1 2 3
4
5

Similar funds

QP
Quilter Plc London, United Kingdom $6.65B AUM 37.83% 1-Year Est. Return
FCBT
First Citizens Bank & Trust Raleigh, North Carolina $6.69B AUM 24.48% 1-Year Est. Return
RWM
Ritholtz Wealth Management New York $6.7B AUM 32.7% 1-Year Est. Return
AWA
Arkadios Wealth Advisors Atlanta, Georgia $6.6B AUM 30.67% 1-Year Est. Return
WHRC
W.H. Reaves & Co Jersey City, New Jersey $6.59B AUM 31.9% 1-Year Est. Return
KGA
K5 Global Advisor Miami Beach, Florida $6.59B AUM
LSERS
Louisiana State Employees Retirement System Baton Rouge, Louisiana $6.74B AUM 53.06% 1-Year Est. Return
CAG
Crestwood Advisors Group Boston, Massachusetts $6.74B AUM 30.22% 1-Year Est. Return

Perceptive Advisors's Q1 2019 Portfolio in Review

As of Q1 2019, Perceptive Advisors held 131 positions worth $3.54B, up 35% from $2.63B the previous quarter. Its ten largest holdings account for 51% of the portfolio.

Perceptive Advisors deployed $107M of net new capital in Q1 2019, opening 31 new positions and adding to 26 existing holdings. Its largest new stake was Array Biopharma Inc: 4,228,900 shares worth $103M.

By sector, the portfolio is most concentrated in Healthcare at 96% of assets, down from 98% a quarter earlier, followed by Miscellaneous and Consumer Staples.

On the sell side, the largest reduction was Neurocrine Biosciences, an estimated $71M trimmed.

  • Perceptive Advisors's largest Q1 2019 buy was Array Biopharma Inc: 4,228,900 shares worth $103M.
  • Perceptive Advisors added most to Mirati Therapeutics, Inc. Common Stock in Q1 2019, an estimated $70.6M increase.
  • Perceptive Advisors's biggest Q1 2019 reduction was Neurocrine Biosciences, cutting an estimated $71M.
  • Perceptive Advisors fully exited Solid Biosciences in Q1 2019, selling an estimated $105M.
  • Perceptive Advisors's ten largest holdings make up 51% of its $3.54B portfolio in Q1 2019.
  • Perceptive Advisors opened 31 new positions and closed 26 in Q1 2019.
  • Perceptive Advisors's portfolio value rose 35% quarter-over-quarter to $3.54B.

Based on Perceptive Advisors's 13F filing for Q1 2019, filed 15 May 2019.